Welcome to LookChem.com Sign In|Join Free

CAS

  • or
AKOS BC-2979, also known as 2-(3-chloropropyl)oxirane, is a colorless liquid organic compound with the molecular formula C6H11ClO. It is primarily used as a chemical intermediate in the production of various other compounds and serves as an important building block for the synthesis of a range of other organic compounds.

3722-44-9 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 3722-44-9 Structure
  • Basic information

    1. Product Name: AKOS BC-2979
    2. Synonyms: IFLAB-BB F0896-0367;AURORA 17265;AKOS BC-2979;OTAVA-BB BB0125340001;3-HYDROXY-7,8,9,10-TETRAHYDRO-6H-BENZO[C]CHROMEN-6-ONE;3-Hydroxy-7,8,9,10-tetrahydro-benzo[c]chromen-6-one;3-hydroxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one
    3. CAS NO:3722-44-9
    4. Molecular Formula: C13H12O3
    5. Molecular Weight: 216.23
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 3722-44-9.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 446.1°C at 760 mmHg
    3. Flash Point: 201.2°C
    4. Appearance: /
    5. Density: 1.34g/cm3
    6. Vapor Pressure: 1.43E-08mmHg at 25°C
    7. Refractive Index: 1.641
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. CAS DataBase Reference: AKOS BC-2979(CAS DataBase Reference)
    11. NIST Chemistry Reference: AKOS BC-2979(3722-44-9)
    12. EPA Substance Registry System: AKOS BC-2979(3722-44-9)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: IRRITANT
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 3722-44-9(Hazardous Substances Data)

3722-44-9 Usage

Uses

Used in Chemical Synthesis Industry:
AKOS BC-2979 is used as a chemical intermediate for the production of various other compounds, contributing to the synthesis of a wide range of organic compounds.
Used in Solvent Applications:
AKOS BC-2979 is used as a solvent in various industrial processes, facilitating the dissolution and interaction of different substances.
Used in Organic Synthesis:
AKOS BC-2979 is utilized in organic synthesis to create new compounds and contribute to the development of novel chemical products.
Used in Pharmaceutical Production:
AKOS BC-2979 is used in the production of pharmaceuticals, playing a role in the synthesis of various medicinal compounds.
Used in Agricultural Chemical Production:
AKOS BC-2979 is employed in the production of agricultural chemicals, aiding in the development of substances used in farming and crop protection.

Check Digit Verification of cas no

The CAS Registry Mumber 3722-44-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,7,2 and 2 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 3722-44:
(6*3)+(5*7)+(4*2)+(3*2)+(2*4)+(1*4)=79
79 % 10 = 9
So 3722-44-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H12O3/c14-8-5-6-10-9-3-1-2-4-11(9)13(15)16-12(10)7-8/h5-7,14H,1-4H2

3722-44-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-hydroxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one

1.2 Other means of identification

Product number -
Other names 7,8,9,10-Tetrahydro-3-hydroxyl-6H-dibenzo<b,d>pyran-6-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3722-44-9 SDS

3722-44-9Relevant articles and documents

Synthesis of Fluorescent Probes Targeting Tumor-Suppressor Protein FHIT and Identification of Apoptosis-Inducing FHIT Inhibitors

Kawaguchi, Mitsuyasu,Sekimoto, Eriko,Ohta, Yuhei,Ieda, Naoya,Murakami, Takashi,Nakagawa, Hidehiko

supporting information, p. 9567 - 9576 (2021/07/19)

For the early diagnosis of cancer, leading to a better chance of full recovery, marker genes whose expression is already altered in precancerous lesions are desirable, and the tumor-suppressor gene FHIT is one candidate. The gene product, FHIT protein, has a unique dinucleoside triphosphate hydrolase (AP3Aase) activity, and in this study, we designed and synthesized a series of FHIT fluorescent probes utilizing this activity. We optimized the probe structure for high and specific reactivity with FHIT and applied the optimized probe in a screening assay for FHIT inhibitors. Screening of a compound library with this assay identified several hits. Structural development of a hit compound afforded potent FHIT inhibitors. These inhibitors induce apoptosis in FHIT-expressing cancers via caspase activation. Our results support the idea that FHIT binders, no matter whether inhibitors or agonists of AP3Aase activity, might be promising anticancer agents.

Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease

Shukur, Karar T.,Ercetin, Tugba,Luise, Chiara,Sippl, Wolfgang,Sirkecioglu, Okan,Ulgen, Mert,Coskun, Goknil P.,Yarim, Mine,Gazi, Mustafa,Gulcan, Hayrettin O.

, (2021/02/01)

A series of urolithin amide (i.e., URO-4–URO-10 and THU-4–THU-10) derivatives was designed and synthesized, and their chemical structures were confirmed with spectroscopic techniques and elemental analysis. The title compounds and synthesis intermediates

Monoterpene-containing substituted coumarins as inhibitors of respiratory syncytial virus (Rsv) replication

Borisevich, Sophia S.,Galochkina, Anastasia V.,Khomenko, Tatyana M.,Korchagina, Dina V.,Nikolaeva, Yulia V.,Petukhova, Galina D.,Salakhutdinov, Nariman F.,Shtro, Anna A.,Volcho, Konstantin P.

, (2021/12/24)

Respiratory syncytial virus (RSV) is a critical cause of infant mortality. However, there are no vaccines and adequate drugs for its treatment. We showed, for the first time, that O-linked coumarin–monoterpene conjugates are effective RSV inhibitors. The most potent compounds are active against both RSV serotypes, A and B. According to the results of the time-of-addition experiment, the conjugates act at the early stages of virus cycle. Based on molecular modelling data, RSV F protein may be considered as a possible target.

Umbelliferyloxymethyl phosphonate compounds-weakly binding zinc ionophores with neuroprotective properties

Connole, Laura,Guesne, Sebastien,Kim, Stephanie,Michael-Titus, Adina T.,Motevalli, Majid,Robson, Lesley,Sullivan, Alice

supporting information, p. 17041 - 17051 (2021/12/10)

Umbelliferone is a member of the coumarin family of compounds which are known for diverse pharmacological activity including in targets relevant to Alzheimers disease, AD. The toxicity associated with some forms of the amyloid protein, Aβ, and the role of Zn2+ (and other biometals) dyshomeostasis in this, are of great interest in AD and make metal ionophore capability desirable in so called multi target drug ligands MTDLs. A new series of umbelliferyloxymethyl phosphonic acid diethylester compounds (umbelliferyloxymethyl phosphonates) bearing a phosphonate at the 7-position (compounds 1, 3-6), hydrolysis products 2, 2a and 2b from 1 and analogues 7 and 8 of 1 with 7-O to 7-S and 1-O to 1-NH substitutions, are reported. Single crystal X-ray structures of compounds 1, 2 and 2a were determined. In terms of neuroprotective properties, the compounds 1, 2, 3, 4, 5 and 6 at 1 μM concentration, inhibited the toxicity of Aβ1-42 (Aβ42) in both toxic Amyloid Derived Diffusible Ligand (ADDL) and fibrillar (fibril) forms towards rat hippocampal cells. Compound 7 displayed cytotoxicity and 8 failed to inhibit Aβ42 toxicity. Concerning compound-metal ionophore activity (assessed using chemical experiments), despite weak binding to Zn2+ determined from 31P NMR titration of 1 and 2 by ZnCl2, compounds 1, 3, 4, 5 and 6 demonstrated ionophore assisted partition of Zn2+ from water to octanol at micromolar concentrations with efficacy on a par with or better than the chelator MTDL clioquinol (5-chloro-7-iodo-8-hydroxyquinoline). Partition was assessed using furnace Atomic Absorption Spectroscopy (AAS). In further experiments interaction of compound 1 with Zn2+ or it's pathways was inferred by (i) delayed fluorescence response with added Zn2+ in cells treated with FluoZin-3 and (ii) by suppression of Zn2+ promoted aggregation of Aβ42.

3-Hydroxy-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one and 3-hydroxy-6H-benzo[c] chromen-6-one act as on-off selective fluorescent sensors for Iron (III) under in vitro and ex vivo conditions

FALLAH, Amirhossein,GüLCAN, Hayrettin Ozan,GAZI, Mustafa,KALKAN, Rasime,SHUKUR, Karar,TERALI, Kerem

, p. 858 - 867 (2021/07/26)

Regarding the abundant use of metals for different purposes, it becomes more critical from various scientific and technological perspectives to discover novel agents as selective probes for the detection of specific metals. In our previous studies, we have shown that aqueous solutions of natural urolithins (i.e., hydroxyl-substituted benzo[c]chromen-6-one derivatives) are selective Iron (III) sensors in fluorescence assays. In this study, we have extrapolated these findings to another coumarine compound (i.e., 3-Hydroxy-7,8,9,10- tetrahydro-6H-benzo[c]chromen-6-one) and compared the selective metal binding properties with Urolithin B (i.e., 3-Hydroxy-6H-benzo[c]chromen-6-one). Following the synthesis and structure identification studies, the fluorometric studies pointed out that the lactam group in the structure still persists to be the important scaffold for maintaining selective on-off sensor capacity that renders the compound a selective Iron (III) binding probe. Moreover, for the first time, fluorescence cellular imaging studies concomitant to cytotoxicity assays with the title compounds were also performed and the results displayed the cell-penetrative, safe, and fluorescent detectable characteristics of the compounds in neuroblastoma and glioblastoma cells through servings as intracellular Iron (III) on-off sensors.

Design, synthesis and characterization of novel urolithin derivatives as cholinesterase inhibitor agents

Norouzbahari, Maryam,Burgaz, Emine V.,Ercetin, Tugba,Fallah, Amirhossein,Foroumadi, Alireza,Firoozpour, Loghman,Sahin, Mustafa F.,Gazi, Mustafa,Gulcan, Hayrettin O.

, p. 1131 - 1140 (2018/11/01)

Background: Considering the limitations of current cholinesterase inhibitor drugs for the treatment of Alzheimer’s disease, there is ongoing research activities to find out alternative drug candidates. The aryl-spacer-N-benzyl pharmacophore model has been effectively utilized to design various types of cholinesterase inhibitor molecules, including donepezil. Within this research study, we have questioned the significance of the benzyl group within this pharmacophore employing the urolithin derivatives. Urolithins are benzo[c]chromene analogue metabolites of ellagitannins, abundantly found in pomegranate and berry fruits. Methods: Employing the previous experience that urolithin-spacer-N-benzyl yielded out potent cholinesterase inhibitors, we have designed novel benzo[c]chromene derivatives either lacking the benzyl group or possessing benzyl group in isoquinoline moiety lacking free N-C bond rotation. Following the synthesis and structure identification studies the compounds were screened for their potential to inhibit cholinesterase enzymes. Furthermore, the title compounds were also evaluated for their potential to prevent cholinesterase-accelerated amyloid beta aggregation. In the final, the most active compound was examined to find out its interactions with the cholinesterase enzyme employing a molecular docking study. Results: The title compounds displayed varying cholinesterase inhibitory potential. Some of the compounds were found more / comparable activity to the activity of the current drugs employed in clinic. The potential of the title molecules to inhibit amyloid beta aggregation was found poor. Conclusion: The title compounds displayed varying cholinesterase inhibitory potential, implying that the benzyl group is not a must in each design. This was also shown with the molecular docking studies. On the other hand, the beta amyloid aggregation studies have pointed out that cholinesterase inhibition does not guarantee the prevention of cholinesterase-accelerated amyloid beta aggregation.

Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation

He, Qi,Liu, Jing,Lan, Jin-Shuai,Ding, Jiaoli,Sun, Yongbing,Fang, Yuanying,Jiang, Neng,Yang, Zunhua,Sun, Liyuan,Jin, Yi,Xie, Sai-Sai

supporting information, p. 512 - 528 (2018/09/29)

A series of new coumarin-dithiocarbamate hybrids were designed and synthesized as multitarget agents for the treatment of Alzheimer's disease. Most of them showed potent and clearly selective inhibition towards AChE and MAO-B. Among these compounds, compound 8f demonstrated the most potent inhibition to AChE with IC50 values of 0.0068 μM and 0.0089 μM for eeAChE and hAChE, respectively. Compound 8g was identified as the most potent inhibitor to hMAO-B, and it is also a good and balanced inhibitor to both hAChE and hMAO-B (0.114 μM for hAChE; 0.101 μM for hMAO-B). Kinetic and molecular modeling studies revealed that 8g was a dual binding site inhibitor for AChE and a competitive inhibitor for MAO-B. Further studies indicated that 8g could penetrate the BBB and exhibit no toxicity on SH-SY5Y neuroblastoma cells. More importantly, 8g did not display any acute toxicity in mice at doses up to 2500 mg/kg and could reverse the cognitive dysfunction of scopolamine-induced AD mice. Overall, these results highlighted 8g as a potential multitarget agent for AD treatment and offered a starting point for design of new multitarget AChE/MAO-B inhibitors based on dithiocarbamate scaffold.

Anti-influenza activity of monoterpene-containing substituted coumarins

Khomenko, Tatyana M.,Zarubaev, Vladimir V.,Orshanskaya, Iana R.,Kadyrova, Renata A.,Sannikova, Victoria A.,Korchagina, Dina V.,Volcho, Konstantin P.,Salakhutdinov, Nariman F.

supporting information, p. 2920 - 2925 (2017/06/01)

Compounds simultaneously carrying the monoterpene and coumarin moieties have been tested for cytotoxicity and inhibition of activity against influenza virus A/California/07/09 (H1N1)pdm09. The structure of substituents in the coumarin framework, as well as the structure and the absolute configuration of the monoterpenoid moiety, are shown to significantly influence the anti-influenza activity and cytotoxicity of the compounds under study. The compounds with a bicyclic pinane framework exhibit the highest selectivity indices (the ratios between the cytotoxicity and the active dose). The derivative of (?)-myrtenol 15c, which is characterized by promising activity, low cytotoxicity, and synthetic accessibility, has the greatest potential among this group of compounds. It exhibited the highest activity when added to the infected cell culture at early stages of viral reproduction.

New inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moieties

Khomenko, Tatyana,Zakharenko, Alexandra,Odarchenko, Tatyana,Arabshahi, Homayon John,Sannikova, Victoriya,Zakharova, Olga,Korchagina, Dina,Reynisson, Jóhannes,Volcho, Konstantin,Salakhutdinov, Nariman,Lavrik, Olga

, p. 5573 - 5581 (2016/10/24)

A number of derivatives of 7-hydroxycoumarins containing aromatic or monoterpene substituents at hydroxy-group were synthesized based on a hit compound from a virtual screen. The ability of these compounds to inhibit tyrosyl-DNA phosphodiesterase I (Tdp 1), important target for anti-cancer therapy, was studied for the first time. It was found that the 7-hydroxycoumarin derivatives with monoterpene pinene moiety are effective inhibitors of Tdp 1 with the most active derivative (+)-25c with IC50value of 0.675?μM. This compound has low cytotoxicity (CC50?>100?μM) when tested against human cancer cells which is crucial for presupposed application in combination with clinically established anticancer drugs. The ability of the new compounds to enhance the cytotoxicity of camptothecin, an established topoisomerase 1 poison, was demonstrated.

Multi-target tacrine-coumarin hybrids: Cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease

Xie, Sai-Sai,Wang, Xiaobing,Jiang, Neng,Yu, Wenying,Wang, Kelvin D.G.,Lan, Jin-Shuai,Li, Zhong-Rui,Kong, Ling-Yi

supporting information, p. 153 - 165 (2015/03/31)

A series of novel tacrine-coumarin hybrids were designed, synthesized and evaluated as multi-target agents against Alzheimer's disease. The biological assays indicated that most of compounds displayed potent inhibitory activity toward AChE and BuChE, and clearly selective inhibition for MAO-B. Among these compounds, 14c exhibited strong inhibitory activity for AChE (IC50 values of 33.63 nM for eeAChE and 16.11 nM for hAChE) and BuChE (IC50 values of 80.72 nM for eqBuChE and 112.72 nM for hBuChE), and the highest inhibitory activity against hMAO-B (IC50 value of 0.24 11/4M). Kinetic and molecular modeling studies revealed that 14c was a mixed-type inhibitor, binding simultaneously to catalytic, peripheral and mid-gorge sites of AChE. It was also a competitive inhibitor, which covered the substrate and entrance cavities of MAO-B. Moreover, 14c could penetrate the CNS and show low cell toxicity. Overall, these results suggested that 14c might be an excellent multi-target agent for AD treatment.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 3722-44-9